Venclexta (Venetoclax)

Venclexta is called Venclyxto in Europe - Save 55% on Abbvie Venclyxto over the US equivalent.

Non-english packaging - English label and English insert included. Plan in advance - allow us 7 days to ship your medicine

Manufacturer for all European Venclyxto: AbbVie Deutschland GmbH & Co. KG Knollstrasse 67061 Ludwigshafen Germany

Information about Venclexta (Venetoclax)

Venclexta (Venetoclax) is an oral medication used primarily in the treatment of certain types of blood cancers, including chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML). It works by targeting and inhibiting BCL-2, a protein that helps cancer cells survive. By blocking BCL-2, Venclexta promotes the death of cancer cells, making it an important therapy in the management of these cancers.

Product Highlights

• Venclexta is approved for the treatment of CLL, a type of cancer that affects the blood and bone marrow, in both previously untreated and relapsed/refractory patients.
• Venclexta is used in combination with other medications for the treatment of AML, a rapidly progressing cancer of the bone marrow and blood, in adults who are ineligible for intensive chemotherapy.
• In some cases, Venclexta is used off-label to treat SLL, a cancer that is closely related to CLL.

Key Ingredient

• Venetoclax

Key Benefits

• Venclexta targets cancer cells specifically, leading to a decrease in the tumor size and potentially improving patient survival outcomes.
• Being available in tablet form, Venclexta is easy to take at home, allowing patients to maintain their treatment regimens without frequent hospital visits for infusions or injections.
• Venclexta can be combined with other agents (such as chemotherapy or rituximab) to increase its efficacy, especially in cancers like CLL and AML.
• It provides an option for patients whose cancer has relapsed or is resistant to other treatments, offering hope where other therapies may have failed.

Direction of Use

• Venclexta is taken orally as a tablet, typically once daily.
• The dosage of Venclexta is individualized based on the type of cancer, the patient's condition, and their response to therapy. For CLL, the typical starting dose is 20 mg daily, gradually increasing to 400 mg daily. The dose may vary when used in combination with other drugs.
• Venclexta should be taken with food to improve absorption and reduce the likelihood of gastrointestinal side effects.
• If you miss a dose, take it as soon as you remember, unless it's nearly time for your next dose. Do not take two doses at once.

Safety Concerns

• A potentially life-threatening condition, TLS occurs when large numbers of cancer cells die rapidly and release their contents into the bloodstream. TLS can lead to kidney failure, arrhythmias, or even death. Close monitoring is required, especially during the first few weeks of treatment.
• Venetoclax can increase the risk of infections due to its effects on the immune system. Patients should be monitored for signs of infections, including fever, chills, or flu-like symptoms.
• Venclexta can cause low blood cell counts, such as neutropenia, anemia, and thrombocytopenia, which may increase the risk of bleeding, bruising, and infections. Regular blood tests are required to monitor these effects.
• Nausea, diarrhea, and vomiting are common side effects. Taking Venclexta with food may help alleviate these symptoms, but they should still be monitored.
• Liver enzymes should be monitored regularly, as Venclexta can cause liver toxicity in some patients.
• Venclexta is not recommended during pregnancy due to potential harm to the fetus. It should also be avoided during breastfeeding, as it may be excreted in breast milk and affect the baby.

Avoid Venclexta (Venetoclax) If

• If you have severe liver dysfunction, Venclexta may not be safe for you, and a different treatment plan should be considered.
• Venclexta should be avoided if you have an active infection that is not under control, as it can suppress immune function and worsen the infection.
• Patients with certain types of cancers, especially those with a large tumor burden, may be at higher risk for TLS. These patients require close monitoring during treatment initiation.
• If you are allergic to venetoclax or any other component of the drug, you should not take it.